Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
Nieuwe tool biedt inzicht in gevolgen borstkanker tot 14 jaar na diagnose
feb 2022 | Borstkanker